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Induction of the immune response against HPV16-associated tumours 
with experimental vaccines 
 
The E6/E7 oncoproteins of human papillomaviruses are expressed in most trans-
formed cells of cervical carcinoma and, therefore, are attractive targets for T cell-mediated 
immunotherapy. We have investigated the capacity of vaccines based on E7 oncoprotein-
derived peptides to induce cellular immune responses and their therapeutic potential for 
treatment of minimal residual disease after surgery in a murine experimental model mi-
micking human HPV16-associated carcinomas. We compared the effect of E749-57 peptide 
(RAHYNIVTF) exhibiting immunodominant epitope recognized by cytotoxic T lymphocy-
tes with E744-62 peptide (QAEPDRAHYNIVTFCCKCD = 8Q) exhibiting CTL, TH and B-
cell epitopes. Immune responses were compared in healthy mice and in mice after surgery 
or chemotherapy of tumours with ifosfamide derivative CBM-4A. Cellular immune re-
sponses were monitored in spleen cells of C57BL/6 mice using ELISPOT-IFN-γ and 51Cr-
release  assay.  Flow  cytometry was used for the detection of  CD4+,  CD8+,  CD4+CD25+,  
Gr-1+CD11b+ and CD3+NK1.1+ populations. 
Vaccination with 8Q peptide and synthetic CpG oligodeoxynucleotide as adjuvant 
induced stronger antitumour immune responses than immunodominant CTL epitope alone 
in both models of minimal residual disease used. We observed the induction of CTL aga-
inst TC-1 cells in the spleen. After in vitro restimulation of splenocytes with peptides, we 
also found an in-creased number of IFN-γ-producing cells. In mice after surgery of TC-1 
tumours, we also observed a stronger therapeutic effect of the 8Q vaccine when it comple-
tely protected mice from tumour residua while RAHYNIVTF vaccine only delayed tumour 
relapse.  
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